Compare Amphastar Pharmaceuticals Inc (AMPH) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MGM Resorts International — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.46 (market cap $826.08M), while MGM Resorts International trades at $47.27 (market cap $11.99B). The key difference: MGM Resorts International is far larger — about 14.5× Amphastar Pharmaceuticals Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MGM | |
|---|---|---|
Market Cap | $826.08M | $11.99B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $50.69 |
52-Week Low | $16.87 | $30.72 |
Enterprise Value | $1.22B | $41.04B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MGM Resorts International (MGM) trades at $46.88, up 0.95% on the day, with a bullish technical signal and mixed earnings history. The stock shows strong revenue growth from $13.1B in 2022 to $17.5B in 2025, though net income margins have compressed to 1.03%. Recent news highlights potential acquisition talks with Barry Diller at $48.30 per share, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook: MGM offers exposure to gaming and hospitality recovery with a reasonable P/S of 0.71, but high P/E of 64.22 reflects margin pressures. Risks include earnings volatility, debt levels, and regulatory scrutiny. The Diller bid provides near-term upside potential, but execution on profitability remains key for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
